Skip To Main Content
Arie Barlev on Muck Rack

Arie Barlev

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Arie

Contact Arie, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Outcomes for patients with EBV-positive PTLD post-allogeneic HCT after failure of rituximab-containing therapy - Bone Marrow Transplantation

|
By Gerard Socie, Jaime Sanz, Irene Garcia-Cadenas, Patrice Chevallier, Franca Fagioli, Deepali Kumar, Per Ljungman, Jan Storek, Arie Barlev
| Nature Verified
Abstract Epstein–Barr virus-positive (EBV+) post-transplant lymphoproliferative disease (PTLD) is an ultra-rare and aggressive condition that may occur following allogeneic hematopoietic cell transplant (HCT) due to immunosuppression. Approximately half of EBV+ PTLD cases are relapsed or refractory (R/R) to initial rituximab-containing therapy.
Open in Who Shared Issue with article?
See all 1 articles